GenMark Diagnostics (GNMK) Reports In-Line Q1 EPS, Maintains FY Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
GenMark Diagnostics Reports Q1 Financial Results
May 5, 2015 4:07 PM EDTFirst Quarter Revenue of $10.1 Million, Up 28% Versus Prior Year
XT-8 Installed Base Expanded by 22 to 562
European ePlex Launch on Track for Fourth Quarter 2015
Full Year Revenue Guidance Maintained at $38-40 Million
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported first quarter 2015 financial results.
As previously reported, revenue for the first quarter of 2015 was $10.1 million, an increase of... More
